



June 18, 2015

BioCryst to Present at the JMP Securities Life Sciences Conference

RESEARCH TRIANGLE PARK, N.C., June 18, 2015 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (Nasdaq:BCRX) today announced that [executives from BioCryst](#) are scheduled to provide a corporate summary and update regarding the Company's programs at the JMP Securities Life Sciences Conference in New York on Tuesday, June 23, 2015 at 3:30 p.m. Eastern Time.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at <http://investor.shareholder.com/biocryst/events.cfm>.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including [BCX4161](#), [BCX7353](#) and other second generation compounds, and [BCX4430](#), a broad spectrum viral RNA polymerase inhibitor. In December 2014, [RAPIVAB](#)TM (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, was approved by the FDA and is available to treat flu patients in the U.S. For more information, please visit the Company's website at www.BioCryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910



Source: BioCryst Pharmaceuticals

News Provided by Acquire Media